Nutraceutical major British Biologicals has unveiled a new product, Supplement –D which is a complete nutrition for diabetics. The company’s Criticare division has researched and developed the product. It is available in vanilla flavour and it is gluten, lactose and sugar free.
Supplement – D has adhered to the guidelines of American Diabetic Association. It is a reno and cardio protective, prevents hypoglycaemia. It contains balanced nutrients which include soluble fibre like FOS, Resistant Starch, monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), antioxidants, vitamins and minerals etc. The product can also be fed to diabetics who are critically ill and also those who have undergone surgery or trauma, anticipating transition to solid food as a result of permanent injury or stroke.
“Diabetes is a chronic illness that requires continuousedical care and support to prevent acute complications and to reduce the long-term risk factors such as Diabetic Retinopathy, Nephropathy, Neuropathy, Stroke etc. Under-feeding is common in diabetic critically ill diabetic patients leading to malnutrition. Maintenance of appropriate nutrition in diabetes is fundamental to patients care. We will continue to focus on the premise that the diabetic state may be prevented or cured through the power of nutritional supplements that are aimed at correcting the nutritional deficiencies before they emerge”, said VS Reddy, managing director, British Biologicals.
“From its range which cover general health with ‘B Protein’, women’s health with ‘Pro PL and ‘Meno Pro’, child health with ‘Kids Pro’ diabetes with ‘D Pro’, cholesterol management with Colred, Liver with ‘Hepa Pro’, weight management with Medislim and Pulmonary distress with Pulmocare, and Pulmoplus, we have found that Hepa Pro, Pulmocare, and Pulmoplus are the fastest growing in the range”, he added.
In 2011, it launched Promaxe and Nutrizen to address the conditions like burns, post surgery and multiple trauma. The company also exports to 16 counties including South East Asia, Africa, Middle East, Russia and the USA. However over 95 percent of its revenues are from the export market.
As a dedicated nutraceutical major, British Biologicals holds a leadership status in a market valued at Rs. 600 crore. In order keep the tempo of growth , it has invested Rs. 150 crore in a greenfield production plant constructed according to USFDA regulations at Jigani Industrial Area, Bangalore on a four acre lot. The plant would span over an area of 1.5 lakh sq. ft, out of which 25,000 sq. ft would be a dedicated area for R&D and quality control labs. The funds has been raised through internal accruals.
Future areas of focus would be neurology and orthopaedic segments which require a nutritional supplement to address the systemic inflammatory response syndrome.
“Going by the promising prospects in the market, we would tap every opportunity for growth. Therefore we are looking to increase manpower strength, devise strategies to augment market share, expand product offering to make the right moves for global forays,” added the British Biologicals chief.
India nutraceutical market is estimated to be Rs. 4,000 crore and players in the space include Abbot, Pfizer, Nestle Nutrition, Novartis, Zydus Cadila, Amway, Pristine and Satva Foods.